Everolimus plus exemestane for hormone resistant metastatic breast cancer (MBC): A single institutional experience.

被引：0
|
作者：
Foltran, Luisa
Bertola, Manuela
Del Conte, Alessandro
Lo Re, Giovanni
Bestetti, Alessandro
Sandri, Paolo
Saracchini, Silvana
机构：
[1] Gen Hosp, Dept Oncol, Pordenone, Italy
[2] Gen Hosp S Maria Angeli, Dept Oncol, Pordenone, Italy
[3] Santa Maria Angeli Hosp, Pordenone, Italy
[4] Santa Maria Angeli Gen Hosp, Pordenone, Italy
[5] S Maria Angeli, Pasiano Di Pordenone, PN, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.e11576
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11576
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Everolimus and its role in hormone-resistant and trastuzumab-resistant metastatic breast cancer
    Keck, Sara
    Glencer, Alexa C.
    Rugo, Hope S.
    FUTURE ONCOLOGY, 2012, 8 (11) : 1383 - 1396
  • [22] EVEROLIMUS PLUS EXEMESTANE VERSUS EVEROLIMUS OR CAPECITABINE MONOTHERAPY IN BREAST CANCER: BOLERO-6
    Ejlertsen, B.
    Jerusalem, G.
    Hurvitz, S.
    De Boer, R.
    Taran, T.
    Sahmoud, T.
    Burris, H.
    BREAST, 2013, 22 : S109 - S109
  • [23] SAFETY OF COMBINED EXEMESTANE AND EVEROLIMUS IN POSTMENOPAUSAL HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER PATIENTS - A RETROSPECTIVE ANALYSIS
    Gilchrist, Jenny
    Todd, J.
    Kefford, R.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 176 - 176
  • [24] Efficacy of fulvestrant in hormone refractory metastatic breast cancer (mBC): a Canadian province experience
    Andrahennadi, S.
    Sami, A.
    Haider, K.
    Chalchal, H.
    Le, D.
    Iqbal, N.
    Ahmed, O.
    Salim, M.
    Manna, M.
    Elgayed, A.
    Wright, P.
    Johnson, K.
    Ahmed, S.
    BREAST, 2021, 56 : S40 - S41
  • [25] COST-EFFECTIVENESS OF EVEROLIMUS FOR ENDOCRINE RESISTANT HR plus METASTATIC BREAST CANCER
    Liu, M.
    Matter-Walstra, K.
    Szucs, T. D.
    Dedes, K. J.
    BREAST, 2013, 22 : S113 - S114
  • [26] Pneumocystis Jirovecii pneumonia (PJP) in metastatic breast cancer (MBC) patients (pts) treated with mTOR inhibitor everolimus (EVE) and exemestane (AI).
    Watson, Geoffrey
    Gullo, Giuseppe
    Zacchia, Alessandra
    Zanoni, Daniele
    Crown, John
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] BRAWO - breast cancer treatment with Afinitor® (Everolimus) and exemestane for ER plus women
    Schuetz, F.
    Jackisch, C.
    Tesch, H.
    Bloch, W.
    Muth, M.
    Kreuzeder, J.
    Lueftner, D.
    ONKOLOGIE, 2013, 36 : 158 - 159
  • [28] Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)
    Moscetti, L.
    Vici, P.
    Sperduti, I.
    Fabbri, M. A.
    Natoli, C.
    Mancini, M. L.
    Sini, V.
    D'Onofrio, L.
    Pizzuti, L.
    Vaccaro, A.
    Magnolfi, E.
    Magri, V.
    Trenta, P.
    Ramponi, S.
    Roma, C.
    Ruggeri, E. M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S282 - S283
  • [29] Safety analysis, correlation with response and previous treatments of the association of everolimus (EVE) and exemestane (EXE) in 181 metastatic breast cancer patients (MBC)
    Moscetti, L.
    Vici, P.
    Sperduti, I.
    Palleschi, M.
    Magri, V.
    Iezzi, L.
    Fabbri, M. A.
    D'Onofrio, L.
    Mentuccia, L.
    Vaccaro, A.
    Trenta, P.
    Ramponi, S.
    Roma, C.
    Ruggeri, E. M.
    ANNALS OF ONCOLOGY, 2015, 26 : 13 - 14
  • [30] BUDGET IMPACT ANALYSIS OF EVEROLIMUS PLUS EXEMESTANE VERSUS GEMCITABINE PLUS PACLITAXEL AND CAPECITABINE PLUS DOCETAXEL IN METASTATIC BREAST CANCER PATIENTS IN EGYPT
    Elsisi, G.
    Saeed, E.
    Elmahdawy, M.
    VALUE IN HEALTH, 2014, 17 (07) : A622 - A622
12345